Temperature control response type gold-iron bimetal nano diagnosis and treatment agent as well as preparation method and application thereof

Through temperature-controlled and responsive gold-iron bimetallic nanodiagnostic agents, combined with multimodal imaging and multiple treatment strategies, the problems of overdose and insufficient imaging guidance in tumor treatment are solved, and efficient in-situ controlled release and multiple collaborative treatment of tumors are achieved, which significantly improves the The accuracy and effectiveness of the treatment.

CN118987281APending Publication Date: 2024-11-22BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410967022.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In tumor treatment, excessive drug use, difficulty in in-situ controlled release of tumors, and lack of multimodal imaging-guided precise diagnosis and treatment strategies, resulting in large side effects and poor efficacy.

Method used

Develop a temperature-controlled and responsive gold iron bimetallic nanodiagnostic agent, a temperature-controlled and responsive mixed fatty acid composed of a core-shell structure of gold iron bimetallic nanocarrier, lauric acid and stearic acid, as well as therapeutic nuclides 177Lu and/or 1,10 -phenanthroline-5,6-dione, used in multimodal imaging-guided collaborative endoradiotherapy, chemotherapy, ferrodynamic therapy, and radiotherapy sensitization therapy.

Benefits of technology

The tumor is controlled and sustained in situ, which improves the tumor diagnosis and treatment efficiency. Through the three-modal imaging-guided four-fold collaborative anti-tumor treatment, the accuracy and effectiveness of the treatment are significantly improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987281A_ABST
    Figure CN118987281A_ABST
Patent Text Reader

Abstract

The invention provides a temperature-control response type gold-iron bimetallic nano diagnosis and treatment agent and a preparation method and application thereof.The temperature-control response type gold-iron bimetallic nano diagnosis and treatment agent comprises a gold-iron bimetallic nano carrier of a core-shell structure, temperature-control response type mixed fatty acid composed of lauric acid and stearic acid, and therapeutic nuclide 177Lu and / or 1, 3-butanediol, the compound is 1, 10-phenanthroline-5, 6-diketone. The nano diagnosis and treatment agent can realize internal radiotherapy, chemotherapy, radiotherapy sensitization treatment and ferroptosis treatment guided by three different modes of imaging of SPECT / CT / MRI, and improves the tumor diagnosis and treatment efficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of nanomedicine technology, and in particular to a temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent and a preparation method and application thereof. Background Art

[0002] Drug overdose, difficulty in controlled release in situ in tumors, and lack of precision diagnosis and treatment strategies guided by multimodal imaging are the main reasons for large side effects and poor efficacy of tumor treatment. In recent years, more and more multifunctional nano-diagnostic agents have been used for drug transport, controlled sustained release, and multimodal imaging-guided combined radiotherapy, chemotherapy, ferroptosis therapy and other synergistic comprehensive treatments. They synergistically kill tumors through multiple treatment strategies and have important development and application prospects. Therefore, the development of nano-diagnostic agents with sustained release function and multimodal imaging-guided comprehensive tumor treatment function will hopefully solve the problems of chemotherapy drugs being difficult to control in situ in tumors, having large side effects, and lacking precision diagnosis and treatment strategies guided by multimodal imaging. Summary of the invention

[0003] The purpose of this application is to provide a temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent to achieve multimodal imaging-guided synergistic internal radiotherapy, chemotherapy, ferroptosis therapy and radiosensitization therapy for tumors, thereby improving the diagnostic and therapeutic efficiency of tumors. The specific technical solution is as follows:

[0004] The first aspect of the present application provides a temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent, which comprises a gold-iron bimetallic nano-carrier with a core-shell structure, a temperature-controlled responsive mixed fatty acid composed of lauric acid and stearic acid, and a therapeutic nuclide. 177 Lu and / or 1,10-phenanthroline-5,6-dione.

[0005] In one embodiment of the present application, the mass ratio of the gold-iron bimetallic nanocarrier to the mixed fatty acid is 10:1-0.1:1, preferably, the mass ratio of the gold-iron bimetallic nanocarrier to the mixed fatty acid is 2:1-0.5:1, and the mass ratio of lauric acid and stearic acid in the mixed fatty acid is 2:1-3:1.

[0006] In one embodiment of the present application, each milligram of gold-iron bimetallic nanocarrier is loaded with 0.05mg-5mg of 1,10-phenanthroline-5,6-dione; and / or, each milligram of gold-iron bimetallic nanocarrier is loaded with 0.05mCi-5mCi of therapeutic nuclide 177 Lu, preferably, 0.5mg-2mg of 1,10-phenanthroline-5,6-dione is loaded per mg of gold-iron bimetallic nanocarrier; and / or, 0.5mCi-2mCi of therapeutic nuclide is loaded per mg of gold-iron bimetallic nanocarrier 177 Lu.

[0007] In one embodiment of the present application, the gold-iron core-shell bimetallic nanocarrier comprises a gold nanocore and an iron nanoshell, the average particle size of the gold nanocore is 3nm-100nm, and the thickness of the iron nanoshell is 1nm-20nm.

[0008] The second aspect of the present application provides a method for preparing the temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent of the present application, which comprises the following steps:

[0009] (1) dispersing the gold-iron bimetallic nanocarrier into pure water to obtain a nanodispersion liquid;

[0010] (2) Preheat the nanodispersion to 36-50°C;

[0011] (3) dissolving lauric acid and stearic acid in an organic solvent to obtain a mixed fatty acid, wherein the organic solvent is selected from at least one of anhydrous methanol, anhydrous ethanol, and dimethyl sulfoxide;

[0012] (4) adding the mixed fatty acid solution to the nano-dispersion liquid, and continuing to heat at 36-50° C. for 0.1-10 hours to obtain a first mixed solution;

[0013] (5) Adding 1,10-phenanthroline-5,6-dione and / or therapeutic nuclide to the first mixed solution 177 Lu, keeping warm at 30-60° C. for 5-20 minutes to obtain a second mixed solution;

[0014] (6) The second mixed solution is placed in a container at a temperature of -5°C to 35°C and incubated for 0.1 to 10 hours, and washed by centrifugation with a buffer solution to obtain a temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent.

[0015] In one embodiment of the present application, the concentration of the nanodispersion is 0.1-10 mg / mL; the concentration of the mixed fatty acid solution is 1-10 mg / mL.

[0016] The third aspect of the present application provides an application of the temperature-controlled responsive gold-iron bimetallic nanodiagnostic and therapeutic agent of the present application in radionuclide-enhanced single photon emission computed tomography (SPECT) imaging, nuclear magnetic resonance (MRI) imaging, and electronic computed tomography (CT) imaging in solid tumors.

[0017] The fourth aspect of the present application provides an application of the temperature-controlled responsive gold-iron bimetallic nano-diagnostic and therapeutic agent of the present application in the comprehensive treatment of tumor imaging-guided in situ chemotherapy, internal radiotherapy, radiotherapy sensitization therapy, and ferroptosis therapy.

[0018] Beneficial effects of this application:

[0019] The present application provides a temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent, which is loaded with therapeutic nuclides through the assistance of mixed fatty acids. 177 Lu and / or 1,10-phenanthroline-5,6-dione. The gold-iron bimetallic nanoparticles contained in the diagnostic and therapeutic agent are loaded with therapeutic nuclides. 177 Lu and / or 1,10-phenanthroline-5,6-dione carrier, which can be used for MRI and CT imaging; 177 Lu can be used for SPECT imaging; the loaded 1,10-phenanthroline-5,6-dione can be used for chemotherapy and radiotherapy sensitization therapy; at the same time, the encapsulated mixed fatty acids can specifically respond to the physiological temperature of the living body (37°C), achieving controlled and sustained release of 1,10-phenanthroline-5,6-dione and therapeutic nuclides in situ in the tumor 177 Lu, gold and iron bimetallic nanoparticles, thus achieving a quadruple synergistic anti-tumor effect of small molecule drug chemotherapy, radionuclide intraradiation therapy, radiosensitization therapy and ferroptosis therapy in situ in the tumor. The quadruple synergistic anti-tumor treatment guided by MRI, CT and SPECT three-modality imaging can greatly improve the efficiency of accurate diagnosis and treatment of tumors.

[0020] Of course, implementing any product or method of the present application does not necessarily require achieving all of the advantages described above at the same time. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application, and for ordinary technicians in this field, other embodiments can also be obtained based on these drawings.

[0022] Figure 1 This is a transmission electron microscope (TEM) image of the gold-iron bimetallic nanocarrier prepared in Example 1 of the present application;

[0023] Figure 2 This is an in situ SPECT imaging image of an animal tumor of the temperature-controlled responsive gold-iron bimetallic nanodiagnostic agent prepared in Example 1 of the present application;

[0024] Figure 3 This is the in vivo CT imaging of the temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent prepared in Example 1 of the present application;

[0025] Figure 4a Animals were injected with saline and therapeutic radionuclides 177Lu, 1,10-phenanthroline-5,6-dione and the gold-iron bimetallic nanocarrier prepared in Comparative Example 1 and the temperature-controlled responsive gold-iron bimetallic nanodiagnostic agent prepared in Examples 1 to 2, the change of tumor volume over time;

[0026] Figure 4b Animals were injected with saline and therapeutic radionuclides 177 Photos of tumors peeled off 14 days after Lu, 1,10-phenanthroline-5,6-dione, and the gold-iron bimetallic nanocarriers prepared in Comparative Example 1, and the temperature-controlled responsive gold-iron bimetallic nanodiagnostic agents prepared in Examples 1 to 2. DETAILED DESCRIPTION

[0027] The following will be combined with the embodiments of the present application and the accompanying drawings to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all the embodiments. All other embodiments obtained by those skilled in the art based on the present application belong to the scope of protection of the present application.

[0028] The first aspect of the present application provides a temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent, which comprises a gold-iron bimetallic nano-carrier with a core-shell structure, a temperature-controlled responsive mixed fatty acid composed of lauric acid and stearic acid, and a therapeutic nuclide. 177 Lu and / or 1,10-phenanthroline-5,6-dione.

[0029] The temperature-controlled responsive gold-iron bimetallic nanodiagnosis and treatment of the present invention is achieved by loading therapeutic nuclides on gold-iron bimetallic nanocarriers. 177 Lu and / or 1,10-phenanthroline-5,6-dione. At the same time, the gold-iron bimetallic nanocarrier can be used for MRI and CT imaging, radiosensitization therapy and ferroptosis therapy. The auxiliary loaded mixed fatty acid can enable the nano-diagnostic agent to release the gold-iron bimetallic nanocarrier at the physiological temperature of the living body (37°C) and be used for SPECT imaging of therapeutic nuclides. 177 Lu and / or the small molecule chemotherapy drug 1,10-phenanthroline-5,6-dione that enhances radiosensitivity, thereby achieving multimodal imaging-guided ferroptosis therapy and multiple synergistic anti-tumor effects of radionuclide intraradiotherapy and / or small molecule drug chemotherapy and radiosensitization therapy, thereby improving the diagnosis and treatment efficiency of tumors.

[0030] In some embodiments, the temperature-controlled responsive gold-iron bimetallic nanotheranostics include a core-shell structured gold-iron bimetallic nanocarrier, a temperature-controlled responsive mixed fatty acid composed of lauric acid and stearic acid, and a therapeutic nuclide. 177 The above diagnostic and therapeutic agent can specifically respond to the physiological temperature of the living body (37°C) and achieve the self-release of therapeutic nuclides in situ in the tumor. 177Lu and gold-iron bimetallic nanoparticles. Gold-iron bimetallic nanoparticles can be used as MRI, CT contrast agents, radiosensitization therapy and ferroptosis therapy, and can also be used as transport nanocarriers to load therapeutic nuclides. 177 Lu, loaded therapeutic nuclide 177 Lu can be used for SPECT imaging, thereby realizing SPECT, MRI, and CT imaging of the tumor in situ, and ultimately realizing multiple treatment methods of combined internal radiotherapy, ferroptosis therapy, and radiotherapy sensitization therapy guided by SPECT, MRI, and CT triple-modality imaging, greatly improving the diagnosis and treatment efficiency of tumors.

[0031] In some embodiments, the temperature-controlled responsive gold-iron bimetallic nano-diagnosis and treatment includes a core-shell gold-iron bimetallic nanocarrier, a temperature-controlled responsive mixed fatty acid composed of lauric acid and stearic acid, and 1,10-phenanthroline-5,6-dione. The above-mentioned diagnostic and therapeutic agent can specifically respond to the physiological temperature of the living body (37°C) to achieve the in situ self-release of 1,10-phenanthroline-5,6-dione and gold-iron bimetallic nanoparticles in the tumor. Gold-iron bimetallic nanoparticles can be used for MRI, CT contrast agents, radiosensitization therapy and ferroptosis therapy, and can also be used as a transport nanocarrier to load the small molecule chemotherapy drug 1,10-phenanthroline-5,6-dione that enhances radiosensitivity, ultimately achieving MRI, CT dual-modality imaging-guided combined chemotherapy, ferroptosis therapy and radiosensitization therapy multiple treatment methods, greatly improving the diagnosis and treatment efficiency of tumors.

[0032] In some embodiments, the temperature-controlled responsive gold-iron bimetallic nanotheranostics include a core-shell structured gold-iron bimetallic nanocarrier, a temperature-controlled responsive mixed fatty acid composed of lauric acid and stearic acid, and a therapeutic nuclide. 177 Lu and 1,10-phenanthroline-5,6-dione. The temperature-controlled responsive gold-iron bimetallic nano-therapeutic agent can specifically respond to the physiological temperature of the living body (37°C) and achieve the in situ self-release of 1,10-phenanthroline-5,6-dione and therapeutic nuclides in the tumor. 177 Lu and gold-iron bimetallic nanoparticles. At the same time, gold-iron bimetallic nanoparticles can be used as MRI, CT contrast agents, radiotherapy sensitization therapy and ferroptosis therapy, and can also be used as transport nanocarriers to load therapeutic nuclides. 177 Lu and the small molecule chemotherapeutic drug 1,10-phenanthroline-5,6-dione for enhanced radiosensitivity, loaded with therapeutic nuclides 177 Lu can be used for SPECT imaging, thereby realizing SPECT, MRI, and CT imaging of the tumor in situ, and ultimately achieving a quadruple treatment method of combined internal radiotherapy, chemotherapy, ferroptosis therapy, and radiosensitization therapy guided by SPECT, MRI, and CT triple-modality imaging, greatly improving the diagnosis and treatment efficiency of tumors.

[0033] In some embodiments of the present application, the mass ratio of the gold-iron bimetallic nanocarrier to the mixed fatty acid is 10:1-0.1:1, preferably, the mass ratio of the gold-iron bimetallic nanocarrier to the mixed fatty acid is 2:1-0.5:1, and the mass ratio of lauric acid to stearic acid in the mixed fatty acid is 2:1-3:1. Controlling the mass ratio of the gold-iron bimetallic nanocarrier to the mixed fatty acid within the above range can make the mixed fatty acid uniformly encapsulated on the gold-iron bimetallic nanocarrier; controlling the mass ratio of the two fatty acids within the above range can make the response temperature of the mixed fatty acid close to the physiological temperature.

[0034] In one embodiment of the present application, each milligram of gold-iron bimetallic nanocarrier is loaded with 0.05mg-5mg of 1,10-phenanthroline-5,6-dione; and / or, each milligram of gold-iron bimetallic nanocarrier is loaded with 0.05mCi-5mCi of therapeutic nuclide 177 Lu, preferably, 0.5mg-2mg of 1,10-phenanthroline-5,6-dione is loaded per mg of gold-iron bimetallic nanocarrier; and / or, 0.5mCi-2mCi of therapeutic nuclide is loaded per mg of gold-iron bimetallic nanocarrier 177 Lu. Control the loading of 1,10-phenanthroline-5,6-dione per mg of gold-iron bimetallic nanocarrier within the above range; and / or load therapeutic nuclides 177 The amount of Lu is controlled within the above range, which can increase the activity of 1,10-phenanthroline-5,6-dione and / or therapeutic nuclides. 177 The loading efficiency and stability of Lu were improved by reducing the free 1,10-phenanthroline-5,6-dione and / or free 177 Lu, reducing preparation costs and side effects.

[0035] In one embodiment of the present application, the gold-iron core-shell bimetallic nanocarrier comprises a gold nanocore and an iron nanoshell, wherein the average particle size of the gold nanocore is 3nm-100nm, and the thickness of the iron nanoshell is 1nm-20nm. By controlling the average particle size of the gold nanocore within the above range and the thickness of the iron nanoshell within the above range, the retention capacity of the gold-iron bimetallic nanodiagnostic agent at the tumor site can be enhanced, while enhancing the tumor treatment effect.

[0036] The second aspect of the present application provides a method for preparing the temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent of the present application, which comprises the following steps:

[0037] (1) dispersing the gold-iron bimetallic nanocarrier into pure water to obtain a nanodispersion liquid;

[0038] (2) Preheat the nanodispersion to 36-50°C;

[0039] (3) dissolving lauric acid and stearic acid in an organic solvent to obtain a mixed fatty acid, wherein the organic solvent is selected from at least one of anhydrous methanol, dimethyl sulfoxide, and anhydrous ethanol;

[0040] (4) adding the mixed fatty acid solution to the nano-dispersion liquid, and continuing to heat at 36-50° C. for 0.1-10 hours to obtain a first mixed solution;

[0041] (5) Adding 1,10-phenanthroline-5,6-dione and / or therapeutic nuclide to the first mixed solution 177 Lu, keeping warm at 30-60° C. for 5-20 minutes to obtain a second mixed solution;

[0042] (6) The second mixed solution is placed in a container at a temperature of -5°C to 35°C and incubated for 0.1 to 10 hours, and washed by centrifugation with a buffer solution to obtain a temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent.

[0043] In one embodiment of the present application, the concentration of the nanodispersion is 0.1-10 mg / mL; the concentration of the mixed fatty acid solution is 1-10 mg / mL. Controlling the concentrations of the nanodispersion and the mixed fatty acid within the above range can improve the preparation efficiency and stability of the temperature-controlled responsive gold-iron bimetallic nanodiagnostic agent, while keeping the temperature response range of the mixed fatty acid near the physiological temperature.

[0044] The temperature-controlled responsive gold-iron bimetallic nanodiagnostic agent prepared by this method has a uniform and stable structure, and the preparation method is simple and easy, which is convenient for large-scale production and application.

[0045] The third aspect of the present application provides an application of the temperature-controlled responsive gold-iron bimetallic nano-diagnostic and therapeutic agent of the present application in radionuclide-enhanced SPECT imaging, nuclear magnetic resonance imaging, and CT imaging in solid tumors.

[0046] The fourth aspect of the present application provides an application of the temperature-controlled responsive gold-iron bimetallic nano-diagnostic and therapeutic agent of the present application in the comprehensive treatment of tumor imaging-guided in situ chemotherapy, internal radiotherapy, radiotherapy sensitization therapy, and ferroptosis therapy.

[0047] Example

[0048] The following examples and comparative examples are given to more specifically describe the embodiments of the present application. Various tests and evaluations were performed according to the following methods. In addition, unless otherwise specified, "parts" and "%" are based on mass.

[0049] Example 1

[0050] <Preparation of gold-iron bimetallic nanocarriers>

[0051] (1) Add 50 mg potassium carbonate (K2 CO 3 ) was dissolved in 200 mL of distilled water to obtain a potassium carbonate solution;

[0052] (2) Add 3 mL of tetrachloroauric acid hydrate (HAuCl 4 ·4H 2 O, 25mmol / L), to obtain a mixed solution;

[0053] (3) aging the mixed solution in the dark for 12 hours;

[0054] (4) After aging, ascorbic acid (final concentration 1.5 mmol / L) was added dropwise under vigorous magnetic stirring and stirring was continued for 30 min;

[0055] (5) By centrifugation (13000r·min -1 ) collecting the obtained gold nanocores;

[0056] (6) The obtained gold nanocores were passed through a polyvinyl pyrrolidone (PVP) aqueous solution (20 g L -1 ) and ethanol, and then redispersed in an ethanol solution;

[0057] (7) 10 mg of gold nanocores were added to 10 mL of thioglycolic acid (0.029 mol / L) ethanol solution and shaken at room temperature for 24 h. The mixture was centrifuged at 13000 r / min. -1 ) The product was recovered and washed with ethanol several times, and then redispersed in ethanol to obtain thioglycolic acid functionalized gold nanocores.

[0058] (8) Disperse 10 mg of functionalized gold nanoparticles in 4 mL of FeCl 3 6H 2 O ethanol solution (2mmol / L) for 15 minutes;

[0059] (9) Add 4 mL of trimesic acid (H 3 BTC) ethanol solution (2 mmol / L), incubated at 70°C for 30 min;

[0060] (10) Repeat the above step (9) three times to obtain an iron nanoshell with a thickness of about 15 nm;

[0061] (11) Pass 12000 r / min -1 The gold-iron bimetallic nanocarrier with core-shell structure was obtained by centrifugation.

[0062] Figure 1This is a transmission electron microscope (TEM) image of the gold-iron bimetallic nanocarrier prepared in Example 1 of the present application. It can be seen that the prepared gold-iron bimetallic nanocarrier has a core-shell structure.

[0063] <Mixed fatty acid-assisted loading of therapeutic nuclides 177 Preparation of temperature-responsive gold-iron bimetallic nanotheranostics based on Lu and 1,10-phenanthroline-5,6-dione>

[0064] (1) Dispersing 10 mg of the prepared gold-iron bimetallic nanocarrier into 9 mL of pure water to obtain a nanodispersion solution (1.11 mg / mL);

[0065] (2) Preheat the above dispersion to 37°C in a water bath.

[0066] (3) Weigh 7.5 mg of lauric acid and 2.5 mg of stearic acid and dissolve them in 1 mL of anhydrous methanol solution to obtain a mixed fatty acid solution (10 mg / mL);

[0067] (4) adding the above-mentioned mixed fatty acid solution to the preheated dispersion and continuing to heat in a 37° C. water bath for 10 minutes to obtain a first mixed solution;

[0068] (5) Add 10 mg of the small molecule chemotherapy drug 1,10-phenanthroline-5,6-dione and 10 mCi of therapeutic radionuclide to the first mixed solution 177 Lu, mix well, and keep warm at 50° C. for 15 minutes to obtain a second mixed solution;

[0069] (6) The second mixed solution was quickly placed in a container containing an ice-water mixture and incubated for 30 minutes. After that, it was fully dispersed by ultrasound and washed three times by centrifugation with PBS to obtain the mixed fatty acid-assisted loaded therapeutic nuclide. 177 Temperature-responsive gold-iron bimetallic nanotheranostics based on Lu and 1,10-phenanthroline-5,6-dione.

[0070] Example 2

[0071] <Preparation of gold-iron bimetallic nanocarriers>

[0072] The preparation steps are the same as those in Example 1.

[0073] <Preparation of temperature-responsive gold-iron bimetallic nanotheranostics loaded with 1,10-phenanthroline-5,6-dione assisted by mixed fatty acids>

[0074] In Example 1, mixed fatty acids assisted loading of therapeutic nuclides 177Preparation of temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent of Lu and 1,10-phenanthroline-5,6-dione> In the preparation step (5), only 1,10-phenanthroline-5,6-dione is added, and the added amount is 10 mg. The other steps are the same as Example 1.

[0075] Comparative Example 1

[0076] <Preparation of gold-iron bimetallic nanocarriers>

[0077] The preparation steps are the same as those in Example 1.

[0078] Test methods and equipment:

[0079] Small Animal SPECT and CT Imaging

[0080] An orthotopic model of mouse breast cancer was established by subcutaneously injecting 1 million 4T1 cells into 8-week-old female athymic (BALB / c) nude mice. 3 50 μg of the temperature-controlled responsive gold-iron bimetallic nanodiagnostic agent prepared in Example 1 was injected into the tumor of the tumor-bearing mice by intratumoral injection. After 6 h, 12 h, and 24 h of injection, small animal SPECT and CT scanning imaging were performed by MOLECUBES, Belgium instruments, respectively. The test results were Figure 2 and Figure 3 .

[0081] Synergistic anti-tumor effect test

[0082] An orthotopic model of mouse breast cancer was established by subcutaneously injecting 1 million 4T1 cells into 8-week-old female athymic (BALB / c) nude mice. 3 At the same time, 50 μL of normal saline (control group), 200 μg of 1,10-phenanthroline-5,6-dione, and 200 μCi of therapeutic radionuclide were injected into the tumor of tumor-bearing mice. 177 Lu, 200 μg of the gold-iron bimetallic nanocarrier prepared in comparative example 1, and 200 μg of the gold-iron bimetallic nanodiagnostic agent prepared in examples 1 to 2. The changes in the tumor volume of mice within 14 days after injection were observed and measured, and the tumor growth curve was drawn. After 14 days of treatment, the tumors in the mice were removed and photographed. The test results were Figure 4a and Figure 4b .

[0083] Result analysis:

[0084] Figure 2 This is the in situ SPECT imaging image of animal tumors of the temperature-controlled responsive gold-iron bimetallic nanodiagnostic agent prepared in Example 1. Figure 3This is the in vivo CT imaging of the temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent prepared in Example 1. It can be seen that the prepared temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent can be used for SPECT imaging and CT imaging. After the injection of mice, the therapeutic nuclide 177 The SPECT imaging signals of Lu are all focused on the tumor site without obvious diffusion, indicating that it has a long-term retention effect and continuous internal radiotherapy effect at the tumor site. The SPECT imaging signals at the tumor site weaken over time, indicating that the therapeutic nuclide 177 Lu has natural attenuation imaging.

[0085] Figure 4a Animals were injected with saline and therapeutic radionuclides 177 Lu, 1,10-phenanthroline-5,6-dione and the gold-iron bimetallic nanocarrier prepared in comparative example 1 and the temperature-controlled responsive gold-iron bimetallic nanodiagnostic agent prepared in examples 1 to 2, the change of tumor volume over time, Figure 4b Animals were injected with saline and therapeutic radionuclides 177 Lu, 1,10-phenanthroline-5,6-dione and the gold-iron bimetallic nanocarrier prepared in comparative example 1 and the temperature-controlled responsive gold-iron bimetallic nanodiagnostic agent prepared in examples 1 to 2. The peeled tumor photos 14 days later show that the injection of the mixed fatty acid prepared in example 1 assisted the loading of therapeutic nuclides. 177 After the temperature-controlled responsive gold-iron bimetallic nanotheranostics were added to the gold-iron bimetallic nanocarrier (Comparative Example 1), the chemotherapy drug 1,10-phenanthroline-5,6-dione and 177 The inhibitory effect of Lu intra-radiotherapy on tumors is limited, which is far lower than the therapeutic effect of the temperature-controlled responsive gold-iron bimetallic nano-diagnostic and therapeutic agent prepared in the examples of the present application.

[0086] It should be noted that the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method or article that includes a series of elements includes not only those elements, but also includes other elements not explicitly listed, or also includes elements inherent to such process, method or article.

[0087] Each embodiment in this specification is described in a related manner, and the same or similar parts between the embodiments can be referenced to each other, and each embodiment focuses on the differences from other embodiments.

[0088] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present application shall be included in the scope of protection of the present application.

Claims

1. A temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent, comprising a gold-iron bimetallic nano-carrier with a core-shell structure, a temperature-controlled responsive mixed fatty acid composed of lauric acid and stearic acid, and a therapeutic nuclide 177 Lu and / or 1,10-phenanthroline-5,6-dione.

2. The temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent according to claim 1, wherein: The mass ratio of the gold-iron bimetallic nanocarrier to the mixed fatty acid is 10:1-0.1:1; The mass ratio of lauric acid to stearic acid in the mixed fatty acid is 2:1-3:

1.

3. The temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent according to claim 1, wherein: The mass ratio of the gold-iron bimetallic nanocarrier to the mixed fatty acid is 2:1-0.5:

1.

4. The temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent according to claim 1, wherein: Each milligram of the gold-iron bimetallic nanocarrier is loaded with 0.05 mg to 5 mg of the 1,10-phenanthroline-5,6-dione; and / or, Each milligram of the gold-iron bimetallic nanocarrier is loaded with 0.05mCi-5mCi of the therapeutic nuclide 177 Lu.

5. The temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent according to claim 1, wherein: Each milligram of the gold-iron bimetallic nanocarrier is loaded with 0.1 mg-2 mg of the 1,10-phenanthroline-5,6-dione; and / or, each milligram of the gold-iron bimetallic nanocarrier is loaded with 0.1 mCi-2 mCi of the therapeutic nuclide 177 Lu.

6. The temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent according to any one of claims 1 to 5, wherein: The gold-iron core-shell bimetallic nanocarrier comprises a gold nanocore and an iron nanoshell, the average particle size of the gold nanocore is 3nm-100nm, and the thickness of the iron nanoshell is 1nm-20nm.

7. A method for preparing a temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent as claimed in any one of claims 1 to 6, wherein: The following steps are involved: dispersing the gold-iron bimetallic nanocarrier into pure water to obtain a nanodispersion liquid; Preheating the nanodispersion to 36-50° C.; Dissolving the lauric acid and stearic acid in an organic solvent to obtain a mixed fatty acid, wherein the organic solvent is selected from at least one of anhydrous methanol, dimethyl sulfoxide, and anhydrous ethanol; Adding the mixed fatty acid solution to the nano-dispersion liquid, and continuing heating at 36-50° C. for 0.1-10 hours to obtain a first mixed solution; Add 1,10-phenanthroline-5,6-dione and / or therapeutic nuclide to the first mixed solution 177 Lu, mix well, and keep warm at 30-60°C for 5-20 minutes to obtain a second mixed solution; The second mixed solution is placed in a container at a temperature of -5°C to 35°C and incubated for 0.1 to 10 hours, and washed by centrifugation with a buffer solution to obtain the temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent.

8. The preparation method according to claim 7, wherein: The concentration of the nano-dispersion liquid is 0.1-10 mg / mL; the concentration of the mixed fatty acid solution is 1-10 mg / mL.

9. An application of the temperature-controlled responsive gold-iron bimetallic nano-diagnostic agent as described in any one of claims 1 to 6 in radionuclide-enhanced SPECT imaging, nuclear magnetic resonance imaging, and CT imaging of solid tumors.

10. An application of a temperature-controlled responsive gold-iron bimetallic nano-therapeutic agent as described in any one of claims 1 to 6 in the combined treatment of tumor imaging-guided in situ chemotherapy, internal radiotherapy, radiosensitization therapy and ferroptosis therapy.

Citation Information

Cited By

  • Cubic gold-iron nano preparation, preparation method and application of cubic gold-iron nano preparation in tumor multi-mode imaging

    CN121648306A

  • Cubic gold nanomaterials, preparation method and application in multi-modal imaging of tumors

    CN121648306B